Home » Huntsville Hospital Stewardship Experience with T2Direct Diagnostics
Huntsville Hospital Stewardship Experience with T2Direct Diagnostics
Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP, Huntsville Hospital, discusses the economic and clinical benefits of T2Direct Diagnostics
In the Science and Industry Showcase, “Managing Sepsis in the Golden Hour: Controlling Costs and Improving Patient Care through Diagnostic Testing,” Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP, Huntsville Hospital, discussed the economic and clinical benefits of T2Direct Diagnostics direct-from-whole blood tests at Huntsville Hospital.
“With the T2Sepsis Solution, our hospital is not only reducing the use of antifungal therapy, we’re also identifying far more infected patients than was possible with blood culture,” said Dr. Edwards.
Dr. Edwards reported the following findings from Huntsville Hospital:
T2Candida detects more Candida infections, days faster than blood culture.
T2Candida provides superior sensitivity as compared to blood culture (94.4% vs. 28% sensitivity). Blood culture missed 26 confirmed Candida infections.
Negative T2Candida results led to cessation or no initiation of antifungal therapy in 64% of patients.
T2Candida improves hospital economics through de-escalation/non-initiation of unnecessary antifungals. T2Candida negative results decreased the duration of micafungin by 2.1 days.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.